SCHEMBL4244107

SCHEMBL4244107

O=Cc1ccc2[nH]c(-c3ccccn3)nc2c1

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 9/20 0.61
METAP1 P53582 8/20 0.61
NPC1 O15118 6/20 0.61
RAB9A P51151 6/20 0.61
PKM P14618 4/20 0.61
LMNA P02545 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
HPGD P15428 2/20 0.61
MTOR P42345 1/20 0.61
KDM4E B2RXH2 3/20 0.61
MAPT P10636 3/20 0.61
KMT2A Q03164 1/20 0.61
CBFB Q13951 10/20 0.58
NPSR1 Q6W5P4 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
TP53 P04637 1/20 0.53
GAA P10253 1/20 0.53
RUNX1 Q01196 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13866553 0.81 NPC1 (0.74) METAP2METAP1NPC1RAB9APKM
SCHEMBL125251 0.80 METAP2 (0.57) METAP2METAP1NPC1RAB9APKM
SCHEMBL125825 0.80 CBFB (0.81) METAP2METAP1NPC1RAB9APKM
SCHEMBL4241271 0.80 NPC1 (0.57) NPC1RAB9ASMN1; SMN2HPGDKDM4E
SCHEMBL13866537 0.79 NPC1 (0.81) METAP2METAP1NPC1RAB9APKM
SCHEMBL124391 0.78 CBFB (0.78) METAP2METAP1NPC1RAB9APKM
SCHEMBL12544900 0.78 METAP2 (0.67) METAP2METAP1NPC1RAB9APKM
SCHEMBL8556415 0.78 METAP2 (0.78) METAP2METAP1NPC1RAB9APKM
SCHEMBL12943863 0.78 METAP2 (0.67) METAP2METAP1NPC1RAB9APKM
SCHEMBL124267 0.78 CBFB (0.78) METAP2METAP1NPC1RAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION 2009-02-19 US disclosed
EP-1993536-A2 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SmithKline Beecham Corporation (US) 2008-11-26 EP disclosed
US-20070249599-A1 Novel Chemical Compounds DUFFY KEVIN J 2007-10-25 US disclosed
WO-2007103755-A2 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2007-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249599-A1 Novel Chemical Compounds HIPK3, HIPK1, HIPK4 METAP2 3559/4885METAP1 3458/4885NPC1 2021/4885
US-20090048252-A1 THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS PIK3CA, BTK, PI4KA METAP2 2081/4885METAP1 1386/4885NPC1 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.